Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids.

Elias BurriJoanna ManganaPhil F ChengAlia SchneiderAchim WeberReinhard DummerEgle Ramelyte

Published in: Journal for immunotherapy of cancer (2024)

Treatment of irHepatitis with infliximab did not result in hepatotoxicity and led to long-lasting positive response in 9 of 10 of the cases. Further research is needed to evaluate the role of anti-TNF antibodies in management of irHepatitis.

Keyphrases

drug induced
ulcerative colitis
rheumatoid arthritis
combination therapy